Prognostic value of galectin-3 in primary cutaneous melanoma

Background Galectin‐3, one of the β‐galactoside‐binding lectins, has been suggested as a marker of disease progression in melanoma patients because of its overexpression observed in recent studies. However, prognostic value of galectin‐3 in primary cutaneous melanoma (PCM) has not been clearly defi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2011-10, Vol.25 (10), p.1174-1181
Hauptverfasser:	Buljan, M., Šitum, M., Tomas, D., Milošević, M., Krušlin, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Biomarkers - metabolism Cohort Studies Disease Progression Female Follow-Up Studies Galectin 3 - metabolism galectin-3 Humans Kaplan-Meier Estimate Male melanoma Melanoma - diagnosis Melanoma - metabolism Melanoma - pathology Middle Aged Prognosis Regression Analysis Retrospective Studies Risk Factors Skin Neoplasms - diagnosis Skin Neoplasms - metabolism Skin Neoplasms - pathology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Galectin‐3, one of the β‐galactoside‐binding lectins, has been suggested as a marker of disease progression in melanoma patients because of its overexpression observed in recent studies. However, prognostic value of galectin‐3 in primary cutaneous melanoma (PCM) has not been clearly defined. Objectives The aim of the study was to analyse whether the intensity of galectin‐3 expression can predict survival in patients with PMC. Methods Galectin‐3 expression was evaluated using immunohistochemistry in 104 PCM samples, including 71 (68.2%) superficial spreading (SSM) and 33 (31.8%) nodular melanomas (NM). Results Significant difference of galectin‐3 expression between SSM and NM was determined (P
ISSN:	0926-9959 1468-3083
DOI:	10.1111/j.1468-3083.2010.03943.x